SK Biopharmaceuticals Co., Ltd.
326030
Rang in Aktien
#4035
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Aktienkurs
$51.93
Marktkapitalisierung
$4.07B
Veränderung (1 Tag)
0.81%
Veränderung (1 Jahr)
-30.58%
Land
KR
Handel SK Biopharmaceuticals Co., Ltd. (326030)
Kategorie
Healthcare
P/B-Verhältnis für SK Biopharmaceuticals Co., Ltd. (326030)
P/B-Verhältnis zum October 2026 TTM: 5.32
Laut den neuesten Finanzberichten und dem Aktienkurs von SK Biopharmaceuticals Co., Ltd. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 5.32. Am Ende des Jahres 2024 lag das P/B-Verhältnis bei 15.93.
P/B-Verlauf für SK Biopharmaceuticals Co., Ltd. von 2011 bis 2026
P/B-Verhältnis zum Jahresende
| Jahr | P/B-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 5.32 | -100.00% |
| 2025 | 0.00 | -100.00% |
| 2024 | 15.93 | -44.04% |
| 2023 | 28.46 | 61.13% |
| 2022 | 17.66 | 3.07% |
| 2021 | 17.14 | -46.44% |
| 2020 | 32.00 | -105.05% |
| 2019 | -633.75 | -570.11% |
| 2018 | 134.81 | 0.30% |
| 2017 | 134.41 | 212.50% |
| 2016 | 43.01 | 22.07% |
| 2015 | 35.23 | 21.42% |
| 2014 | 29.02 | -14.39% |
| 2013 | 33.89 | 23.27% |
| 2012 | 27.50 | 16.93% |
| 2011 | 23.51 | 0.00% |
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/B-Verhältnis | P/B-Verhältnis-Differenz | Land |
|---|---|---|---|
| 6.251 | 17.52% |
US
|
|
| 13.2547 | 149.19% |
US
|
|
| 4.208 | -20.89% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 16.23% |
NL
|
